The Phase II study on the efficacy and safety of weekly nab-paclitaxel with 3 rd line therapy or more of advanced or recurrent non-small cell lung cancer after disease progression on 2nd line therapy or more - The Phase II study on the efficacy and safety of weekly nab-paclitaxel with 3 rd line therapy or more of advanced or recurrent non-small cell lung cancer after disease progression on 2nd line therapy or more

Division of Medical Oncology Department of Internal Medicine Teikyo University School of Medicine0 个研究点目标入组 36 人开始时间: 2016年8月25日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1.Patients with paclitaxel treatment history. 2.Patients with hypersensitivity to paclitaxel or preparations containing albumin. 3.Patients with active double cancer in need of treatment. However it is not excluded that carcinoma in situ that is judged to be healing by local treatment, intramucosal cancer equivalent of lesions or other cancers unlikely in need of treatment. 4.The infection requiring systemic treatment (including patient of HBs antigen-positive). 5.Serious complications (heart disease, interstitial pneumonia, uncontrolled high blood pressure or diabetes, etc.) 6.there is a possibility of pregnancy or during pregnancy or lactating women. 7.Patients with psychosis or psychotic symptoms is determined to be difficult to participants in a clinical trial. 8.Patients during systemic administration steroids therapy(oral or intravenous). 9.Patients with symptomatic brain metastases. 10.Other, cases physicians it is judged unsuitable for registration of this clinical trial.

发起方

Division of Medical Oncology Department of Internal Medicine Teikyo University School of Medicine